Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Rasime Kalkan

Rasime Kalkan

Near East University, Turkey

Title: Epigenetics and treatment planning for primary glioblastoma

Biography

Biography: Rasime Kalkan

Abstract

Background: To establish the frequency of MGMT and RARβ methylation in primary glioblastomas. We screened primary glioblastoma multiforme (GBM) in a population-based study for MGMT and RARβ methylation and correlated them with clinical data and treatment. Results: MGMT methylation was detected in 13 of the 40 patients (32,5%). MGMT-promoter methylation did not correlate with overall survival (OS; p >0.05). RARB methylation was detected in 24 of the 40 patients (60%). The overall survival time of the patients with methylated RARβ was 19 months, and nonmethylated RARB was 15 months. There was statically (OS;p<0,05) significance between the patients who were treated with chemotherapy and radiotherapy.
Conclusion: In summary, this study is suggested to the RARβ gene is also a new prognostic and predictive candidate marker for the primary GBM patients for choosing therapy strategy. Furthermore MGMT promoter methylation had no prognostic value and lower frequency in primary glioblastomas.